263 related articles for article (PubMed ID: 15226619)
1. [Gemtuzumab ozogamicin and targeted cancer therapy].
Imaizumi M
Nihon Yakurigaku Zasshi; 2004 Jul; 124(1):25-9. PubMed ID: 15226619
[TBL] [Abstract][Full Text] [Related]
2. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
3. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Stadtmauer EA
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
[TBL] [Abstract][Full Text] [Related]
4. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.
Damle NK
Expert Opin Biol Ther; 2004 Sep; 4(9):1445-52. PubMed ID: 15335312
[TBL] [Abstract][Full Text] [Related]
5. Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?
O'Hear C; Rubnitz JE
Expert Rev Hematol; 2014 Aug; 7(4):427-9. PubMed ID: 24871925
[TBL] [Abstract][Full Text] [Related]
6. In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.
Petrich T; Korkmaz Z; Krull D; Frömke C; Meyer GJ; Knapp WH
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):851-61. PubMed ID: 20107790
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse.
Sievers EL
Expert Opin Biol Ther; 2001 Sep; 1(5):893-901. PubMed ID: 11728223
[TBL] [Abstract][Full Text] [Related]
8. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
Linenberger ML
Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
[TBL] [Abstract][Full Text] [Related]
9. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
Gbadamosi M; Meshinchi S; Lamba JK
Future Oncol; 2018 Dec; 14(30):3199-3213. PubMed ID: 30039981
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS
J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753
[TBL] [Abstract][Full Text] [Related]
11. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
12. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
Stadtmauer EA
Curr Oncol Rep; 2002 Sep; 4(5):375-80. PubMed ID: 12162910
[TBL] [Abstract][Full Text] [Related]
13. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia.
Fenton C; Perry CM
Drugs; 2005; 65(16):2405-27. PubMed ID: 16266206
[TBL] [Abstract][Full Text] [Related]
14. [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient].
Ogura K; Machida T; Nara M; Mayama K; Akagi T; Kubo K
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1881-3. PubMed ID: 18030030
[TBL] [Abstract][Full Text] [Related]
15. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
Walter RB; Boyle KM; Appelbaum FR; Bernstein ID; Pagel JM
Blood; 2008 May; 111(9):4813-6. PubMed ID: 18326813
[TBL] [Abstract][Full Text] [Related]
16. Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.
Duong HK; Sekeres MA
Clin Interv Aging; 2009; 4():197-205. PubMed ID: 19503782
[TBL] [Abstract][Full Text] [Related]
17. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
Baron J; Wang ES
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):549-559. PubMed ID: 29787320
[TBL] [Abstract][Full Text] [Related]
18. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.
Leopold LH; Berger MS; Feingold J
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S29-34. PubMed ID: 11970768
[TBL] [Abstract][Full Text] [Related]
19. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
[TBL] [Abstract][Full Text] [Related]
20. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
Shannon-Dorcy K
Oncol Nurs Forum; 2002 May; 29(4):E52-9. PubMed ID: 12011919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]